China Meheco Group 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...4567891011121314...212213»
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease. (Pubmed Central) -  Mar 18, 2024   
    The SARS-CoV-2 main protease (Mpro) plays a central role in the replication of the virus and represents an attractive drug target. Herein, we report the discovery of novel SARS-CoV-2 Mpro covalent inhibitors, including highly effective compound NIP-22c which displays high potency against several key variants and clinically relevant nirmatrelvir Mpro E166V mutants.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Emerging data in COVID-19 create urgent challengers for health providers: Updates on COVID-19 vaccine and Paxlovid. (Pubmed Central) -  Mar 18, 2024   
    At present, health providers should counsel all their patients about masking, social distancing, and avoiding crowds, especially indoors where regions of extreme weather conditions are keeping people indoors in closed quarters. In the treatment of COVID-19 the major clinical challenge to health providers, especially in their Black patients, is to prescribe Paxlovid during the first 5 days after onset of symptoms and a positive test.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, bebtelovimab (LY-CoV1404) / AbCellera, Eli Lilly, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Evaluation of Physicians Prescribing of COVID-19 Guideline-Directed Outpatient Treatments in a Primary Care Walk-In Clinic. (Pubmed Central) -  Mar 18, 2024   
    Nirmatrelvir-ritonavir was the most prescribed medication for the treatment of mild-to-moderate COVID-19, consistent with its position as first-line therapy and widespread accessibility. The study results will inform future educational opportunities, such as in-service presentations and handouts, that may improve the prescribing of outpatient treatment for mild-to-moderate COVID-19 moving forward.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Victrelis (boceprevir) / Roche, Merck (MSD), Xocova (ensitrelvir) / Shionogi
    Journal:  An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. (Pubmed Central) -  Mar 17, 2024   
    Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the presence of resistance-conferring mutations in sequenced viral genomes raises concerns about future drug resistance...We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 Mpro more efficiently than existing drugs...Last, ML2006a4 was found to be less sensitive to several mutations that cause resistance to NTV or ETV and occur in the natural SARS-CoV-2 population. Thus, anticipatory design can preemptively address potential resistance mechanisms to expand future treatment options against coronavirus variants.
  • ||||||||||  interferon ? biobetter (ABN101) / Abion
    Inhalable Interferon-beta Bio-better, ABN101 Dry Powder, Inhibits and Reduces the Infection of Respiratory Viruses in Non-human Primates (NHPs) (San Diego Convention Center, Area H (Hall H, Ground Level)) -  Mar 17, 2024 - Abstract #ATS2024ATS_9290;    
    Interestingly, ABN101 DP pre-treated group showed the lowest virus titers for both viruses, which indicated that ABN101 DP can be utilized as prophylactic treatment for respiratory viruses. Conclusions In conclusion, ABN101 DP delivered through inhalation can reduce virus titers of IAV and SARS-CoV-2 in NHPs, which may prove ABN101 DP has the potential broad-spectrum anti-respiratory virus therapeutics for pandemic preparedness.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Understanding Racial Disparities: Hospitalization and Mortality in Chronic Lung Diseases and COVID-19 Patients (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) -  Mar 17, 2024 - Abstract #ATS2024ATS_9224;    
    We used at-home COVID-19 treatment (e. g. Paxlovid) prescribing data to assess the relationship between at-home COVID-19 prescribing practices and hospitalization and mortality by race/ethnicity for adult patients...Black and Hispanic patients with chronic lung diseases had higher deaths associated with a COVID-19 infection. Inequitable access and quality healthcare, alongside longstanding social and economic factors, contribute to increased mortality for racial and ethnic minoritized groups.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Nirmatrelvir/Ritonavir Reduces COVID-19 Symptom Duration Across Subgroups of Patients at High Risk (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_918;    
    NCT05438602 Nirmatrelvir/r treatment reduced median times to sustained alleviation and resolution of all targeted COVID-19 symptoms vs PBO significantly overall, and consistently across pt subgroups (by baseline symptom severity, serostatus, VL, time since symptom onset, sex and age) in pts at high risk for progressing to severe disease.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Large Fraction of COVID-19 Hospitalizations Preventable With Oral SARS-CoV-2 Antiviral Treatment (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_917;    
    This noteworthy finding is attributed to the strong observed protective effect of treatment coupled with large treatment gaps. Moreover, the diminished protection among immunocompromised patients underscores the importance of close symptom monitoring and consideration of additional therapeutic options such as remdesivir and COVID-19 convalescent plasma.
  • ||||||||||  Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Pooled Analysis of Randomized Trials Comparing Drug Efficacy for Early COVID-19 During Omicron Waves (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_914;    
    P3
    Given the low number of events, the study produced no evidence on the other comparisons. No significant difference in symptom prevalence over time across the arms was found.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    AGILE CST-8 Phase I Trial of Combined Nirmatrelvir/r and Molnupiravir for Mild-Moderate COVID-19 (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_913;    
    P1/2
    This first report of combination nirmatrelvir/ritonavir with molnupiravir confirms safety and tolerability at full doses used in adults. The clinical and virological benefit of this combination should be tested in larger phase II studies.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Journal:  Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies. (Pubmed Central) -  Mar 16, 2024   
    Patients with hematologic malignancies and non-severe COVID-19 who received nirmatrelvir/ritonavir experienced faster decrease in viral load and shorter viral shedding. Furthermore, besides the advantage of oral administration, nirmatrelvir/ritonavir administration reduced the need of hospital admission.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Trial completion date, Trial primary completion date:  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (clinicaltrials.gov) -  Mar 12, 2024   
    P2,  N=900, Enrolling by invitation, 
    In the treatment of mild-to-moderate COVID-19 in cancer patients, Molnupiravir was comparable to Nirmatrelvir/Ritonavir in preventing progression to severe disease/death and rebound events, and it had a superior safety profile. Trial completion date: Jul 2024 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Jul 2025
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    A path to industry from a primarily undergraduate institution (In-person; Room 344 (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_11979;    
    She developed her expertise in organic synthesis, reaction optimization, and parallel medicinal chemistry as a Scientific Summer Scholar at NIBR in 2016, a Summer Student worker at Pfizer Groton in 2017, and now as a Senior Scientist in Medicinal Chemistry at Pfizer Groton since 2018. Starting her career as an entry level MS chemist, she will detail how her mentors shaped her career trajectory and now, six years later, how she has grown into leadership roles on her projects across a range of therapeutic areas: from Rare Disease and Internal Medicine to Antivirals, notably including the discovery of Paxlovid
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Design of novel sustainable pathways for the synthesis of the key intermediates of nirmatrelvir (Virtual; Virtual Session (Virtual Only)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_7921;    
    The reactions were made green and more efficient using catalytic methods, such as solid acid-catalyzed dehydration, catalytic alkene metathesis, and catalytic oxidation. By developing greener and more efficient pathways while also minimizing waste, the cost and environmental burden of production of the drug can be kept low, helping to ensure that the drug is available to all.
  • ||||||||||  Camzyos (mavacamten) / BMS, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    A Targeted Review of NICE, CADTH and ICER Assessments: An Evaluation of the Joint Position Statement () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_275;    
    Despite the objective to increase collaboration between countries, the selection criteria differ between NICE, ICER and CADTH, resulting in varying reimbursement decisions. Further assessment and monitoring of this collaboration is required to fully evaluate the success of the Joint Position Statement.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Analysis of Emergent SARS-CoV-2 Antiviral Resistance and Its Association With Virologic Rebound () -  Mar 5, 2024 - Abstract #CROI2024CROI_208;    
    Mutations that confer resistance emerge with N-R and RDV treatment, but they are transient, present at minor frequencies, and are not associated with virologic rebound. These data suggest that the risk of widespread dissemination of significant drug resistance to N-R and RDV remains low.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Molnupiravir Does Not Increase 3CLpro Resistance Mutations When Co-Administered With Nirmatrelvir/r () -  Mar 5, 2024 - Abstract #CROI2024CROI_206;    
    Our results suggest that co-administration of NMV/r lowered the magnitude of the mutagenetic effect of MOV against SARS-CoV-2, likely due to the additive effect of the combination therapy on reduced rounds of viral replication. There is no evidence that combination therapy potentiated selection for NMV resistance mutations during 4 days of treatment.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Clinical, Journal:  Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews. (Pubmed Central) -  Mar 4, 2024   
    There is low to moderate certainty of evidence from SRs that nirmatrelvir/ritonavir reduces mortality, clinical progression and hospitalization rate in COVID-19 patients compared with controls, without increasing the occurrence of overall and serious adverse events. Based on the overall methodological assessment, on average we can have high confidence in the quality of results generated by the SRs.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  CT-based Assessment at 6-Month Follow-up of COVID-19 Pneumonia patients in China. (Pubmed Central) -  Feb 29, 2024   
    The 6-month follow-up CT of recent COVID-19 pneumonia cases in China showed a considerable proportion of the patients with pulmonary residual abnormalities and fibrotic-like changes. Antivirals against SARS-CoV-2 like paxlovid may be beneficial for long-term regression of COVID-19 pneumonia.